Phase I/II Trial of Electroporation-Delivered pBI-4 Vaccine (TriGrid™ PVX4) for Treatment of Women With HPV16-Positive CIN1 or Persistent Infection

STUDY OVERVIEW AND TRIAL DESIGN This study is a randomized, double‐blind,placebo‐controlled, multicenter Phase II clinical trial in Taiwan to evaluate the safety,efficacy, tolerability, and immunogenicity of the pBI‐4 therapeutic DNA vaccineadministered via the clinical‐stage Intramuscular TriGrid™ Delivery System version 2.0(TDS‐IM v2.0) [1‐4]. The target study population consists of adult female subjects aged19 years and older who have biopsy‐confirmed Grade 1 cervical intraepithelial neoplasia(CIN1) with concurrent Human Papillomavirus type 16 (HPV16) infection, or who exhibitpersistent (defined as 6 months or longer) HPV16 infection with normal cytology (CIN<1)[5‐8].A maximum target of 94 eligible subjects will be enrolled and randomized in a 1:1 ratiointo two parallel groups: 47 subjects in the active pBI‐4 vaccine group and 47 subjectsin the placebo group [1, 4, 9].THERAPEUTIC VACCINE AND ELECTROPORATION DELIVERY MECHANISM The investigational drug,pBI‐4, is a clinical‐grade, 6,999 base‐pair circular plasmid DNA vaccine [10‐12]. It isengineered to express human calreticulin (CRT) linked to codon‐optimized HPV16 E6, E7,and L2 residues (amino acids 11‐200) [11]. To ensure clinical safety, the gene sequencesencoding the HPV16 E6 and E7 proteins incorporate specific mutations that disable theirnative oncogenic functions [10, 11, 13].The vaccine (at a dose of 1.0 mg in 1.0 mL volume) or placebo (1.0 mL ofphosphate‐buffered saline) is administered intramuscularly into the vastus lateralis(thigh) muscle [1, 14, 15]. To overcome the historical limitation of low cellular DNAuptake in humans, the trial utilizes the automated TDS‐IM v2.0 delivery system [14,16‐18]. During the automated administration sequence (which takes approximately 10seconds), the device deploys an injection needle and four surrounding electrodes into themuscle [19]. Following fluid delivery, short, mild electrical pulses are applied to thelocal tissue [19]. This electroporation process transiently opens pores in cellmembranes, enhancing intracellular plasmid DNA uptake and antigen expression by 2 to 3orders of magnitude compared to standard needle injections [16, 19, 20].TWO‐STAGE ADAPTIVE REGIMEN MODIFICATION The trial employs a two‐stage group‐sequentialdesign featuring a pre‐specified, non‐binding adaptive regimen modification [3, 21]. Asingle interim analysis will be conducted by an independent Data Safety Monitoring Board(DSMB) once approximately 50% of the randomized participants (approximately 42 patients)complete their Month 6 primary assessment [9, 22].At the interim analysis, the DSMB will calculate the conditional power (CP) based on theprimary efficacy endpoint (HPV16 clearance rate) under the design alternative (assuming a60% clearance rate in the vaccine group versus a 30% clearance rate in the placebo group)[9, 21, 23]. ‐ If the conditional power is calculated to be less than 20% (indicating suboptimalefficacy of the single‐dose regimen), the trial will trigger a non‐binding futilityrule and adaptively switch to a two‐dose (prime‐boost) regimen for all remainingparticipants enrolled in Stage 2 [21]. Under this adapted schedule, Stage 2participants will receive their first dose at Month 0 and a booster dose at Month 2,while maintaining double‐blind placebo control and 1:1 randomization [21, 24]. ‐ If the conditional power is 20% or higher, the trial will continue with the originalsingle‐dose regimen for the rest of the study [21].CLINICAL EVALUATIONS AND FOLLOW‐UP TIMELINEAll participating subjects will undergo structured clinical assessments across multiplevisits: 1. Baseline/Screening (Month ‐1 to 0): Obtaining written informed consent, checkingfull eligibility, medical and gynecological history, physical examination with ECOGperformance status, vital signs, clinical laboratory tests (including complete bloodcount with differential, serum chemistry, HIV, Hepatitis B and C screenings), urinepregnancy test, Pap smear, Roche Cobas HPV genotyping, and colposcopy withendocervical curettage (ECC) and mandatory tissue biopsy [6, 25‐27]. 2. Vaccination Visit (Month 0 Day 1): Pre‐dose physical exam, vital signs, urinepregnancy test, and a research blood draw (serum and peripheral blood mononuclearcells) for baseline HPV16‐specific humoral and cell‐mediated immune assessments [14,28‐30]. Following the pBI‐4 or placebo injection via TDS‐IM v2.0, subjects areobserved on‐site for up to 60 minutes, with vital signs recorded at 30 and 60minutes post‐dose to monitor for potential immediate hypersensitivity or vasovagalreactions [14, 30‐32]. 3. Post‐Vaccination Phone Call (Week 1 / Day 8): A telephone interview to record anylocal reactogenicity, systemic adverse events, and concomitant medications,alongside the administration of the Procedure Tolerability Questionnaire to measurepain (using a 10‐point Visual Analog Scale) and device acceptability [29, 31‐33]. 4. Month 6 Follow‐Up Visit: Physical exam, vital signs, safety laboratory tests,research blood draw for immunologic response, Pap smear, Roche Cobas HPV genotyping,and colposcopy with ECC (with biopsy performed only if clinically indicated) [29,34‐36]. 5. Month 12 Follow‐Up Visit (Final Evaluation): A replication of the Month 6 visitassessments, representing the completion of the 12‐month post‐vaccination follow‐upperiod.If the adaptive two‐dose regimen is triggered, Stage 2 participants will undergo anadditional vaccination visit at Month 2 Day 1 (with pre‐dose safety labs and a pregnancytest) and a subsequent post‐vaccination telephone call at Week 9 to document tolerabilityand safety parameters [24, 40].